Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study
| Autor: | Richard, M.‐a., Paul, C., de Pouvourville, G., Jullien, D., Mahe, E., Bachelez, H., Seneschal, J., Misery, L., Aubert, R., Reguiai, Z., Shourick, J., Taieb, C., Joly, P., Ezzedine, K. |
|---|---|
| Přispěvatelé: | Essec Business School, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Victor Dupouy, Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB), Laboratoire sur les interactions Epithéliums Neurones (LIEN), Université de Brest (UBO), Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Toulouse [Toulouse], European Market Maintenance Assessment [Fontenay-sous-Bois] (EMMA ), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
vitiligo
Mesures adjuvantes MESH: Interferon-gamma Associated measures MESH: Long-Term Care MESH: Skin interferon-γ MESH: Melanocytes MESH: Physicians MESH: Surveys and Questionnaires skin and connective tissue diseases Prescriber Systemic glucocorticoid therapy MESH: Humans MESH: Long Term Adverse Effects MESH: Middle Aged integumentary system Corticothérapies systémiques pathogenesis MESH: Polypharmacy cytotoxic CD8+ T cells targeted therapies MESH: Keratinocytes MESH: Male Prescripteur MESH: Practice Patterns Physicians' MESH: Specialization MESH: Vitiligo [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology Journal of the European Academy of Dermatology and Venereology, Wiley, 2021, 35 (4), pp.912-918. ⟨10.1111/jdv.17000⟩ |
| ISSN: | 0926-9959 1468-3083 |
| DOI: | 10.1111/jdv.17000⟩ |
| Popis: | International audience; Vitiligo is the most common depigmenting disorder affecting 0.1%-2% of the population worldwide. The characteristic white patches result from the selective loss of melanocytes. Sustained recent efforts have resulted in a detailed understanding of the genetic architecture of vitiligo. About 80% of vitiligo risk is attributable to genetic factors; and the rest (20%) is attributable to the environment. Over the past decade, substantial progress has been made in our understanding of the pathogenesis of vitiligo which is now clearly classified as an autoimmune disease. Melanocytes from patients with vitiligo are more susceptible to oxidative stress which begets the release of exosomes and inflammatory cytokines that will lead to activation of the innate immune response and subsequently to adaptive immune response through activation of autoreactive cytotoxic CD8+ T cells. These produce interferon-γ (IFN-γ) which promotes disease progression through IFN-γ-induced chemokine secretion from surrounding keratinocytes to further recruit T cells to the skin through a positive feedback loop. CD8 tissue-resident memory T cells are in turn responsible for long-term maintenance and potential relapse of vitiligo in human patients through cytokine-mediated recruitment of T cells from the circulation. This review summarizes the current knowledge on vitiligo and attempt to give an overview of the future in vitiligo treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text